20:12:58 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-27 Kvartalsrapport 2024-Q2
2024-03-25 X-dag ordinarie utdelning FARON 0.00 EUR
2024-03-22 Årsstämma 2024
2024-03-14 Bokslutskommuniké 2023
2023-08-29 Kvartalsrapport 2023-Q2
2023-03-27 X-dag ordinarie utdelning FARON 0.00 EUR
2023-03-24 Årsstämma 2023
2023-03-03 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-07-07 Extra Bolagsstämma 2022
2022-04-25 X-dag ordinarie utdelning FARON 0.00 EUR
2022-04-22 Årsstämma 2022
2022-03-25 Bokslutskommuniké 2021
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-26 X-dag ordinarie utdelning FARON 0.00 EUR
2021-04-23 Årsstämma 2021
2021-03-25 Bokslutskommuniké 2020
2020-05-14 X-dag ordinarie utdelning FARON 0.00 EUR
2020-05-13 Årsstämma 2020
2020-03-20 Bokslutskommuniké 2019

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriBioteknik
Faron Pharmaceuticals är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling av terapeutiska lösningar som används för behandling av immuna sjukdomar och diverse organskador. Störst verksamhet återfinns inom Nordamerika samt Europa, med sjukhus och forskningsinstitut som dominerande kundbas. Utöver huvudverksamheten erbjuds diverse mervärdestjänster. Huvudkontoret ligger i Turku.
2022-01-31 14:30:00

TR-1: Standard form for notification of major holdings

[][][][][][][][]
NOTIFICATION OF
MAJOR HOLDINGS
(to
be sent to the
relevant issuer
and
to the FCA in
Microsoft Word
format
if possible)[i]

1a. Identity of Faron Pharmaceuticals
the issuer or the Ltd
underlying issuer
of existing
shares
to which voting
rights are
attached[ii]:[ ]
1b. Please
indicate if the
issuer is
a non-UK issuer 
(please mark with
an "X" if
appropriate)
Non-UK issuer X
2. Reason for the
notification
(please mark the
appropriate box
or
boxes with an
"X")
An acquisition or x
disposal of
voting
rights
An acquisition or x
disposal of
financial
instruments
An event changing
the breakdown of
voting rights
Other (please
specify)[iii]:
(Decrease of
holding due to
issuance
of new shares)
3. Details of
person subject to
the
notification
obligation[iv]
Name Timo Syrjälä
City and country
of registered
office (if
applicable)
4. Full name of
shareholder(s)
(if
different from
3.)[v]
Name
City and country
of registered
office (if
applicable)
5. Date on which 28.01.2022
the threshold was
crossed or
reached[vi]:
6. Date on which 31.01.2022
issuer notified
(DD/MM/YYYY):
7. Total
positions of
person(s)
subject to the
notification
obligation
% of voting % of voting Total of both Total
rights rights in % (8.A + number of
attached to through 8.B) voting
shares financial rights of
(total instruments issuer[vii]
of 8. A) (total of
8.B 1 + 8.B
2)
Resulting 17.27% 17.27%  53.232.032
situation on the
date on
which threshold
was crossed or
reached
Position of 16.67% 16.67%
previous
notification
(if applicable)

[][][][][][][]
8. Notified
details of the
resulting
situation on
the date on
which the
threshold was
crossed or
reached[viii]
A: Voting
rights
attached to
shares
Class/type of Number of % of voting rights
sharesISIN voting
code (if rights[ix]
possible)
Direct(Art 9 Indirect(Art Direct(Art 9 of Indirect(Art 10 of
of Directive 10 of Directive Directive 2004/109/EC)
2004/109/EC) Directive 2004/109/EC) (DTR5.2.1)
(DTR5.1) 2004/109/EC) (DTR5.1)
(DTR5.2.1)
FI4000153309 2.663.573 6.528.926 5.00% 12.27%

SUBTOTAL 8. A 9.192.499 17.27%

B 1: Financial
Instruments
according to
Art. 13(1)(a)
of Directive
2004/109/EC
(DTR5.3.1.1
(a))
Type of Expiration Exercise/ Number of voting % of
financial date[x] Conversion rights that may be voting
instrument Period[xi] acquired if the rights
instrument is
exercised/converted.

SUBTOTAL
8. B 1

B 2: Financial
Instruments
with similar
economic
effect
according to
Art. 13(1)(b)
of Directive
2004/109/EC
(DTR5.3.1.1
(b))
Type of Expiration Exercise/ Physical or Number of % of
financial date[x] Conversion cash voting voting
instrument Period settlement[xii] rights rights
[xi]

SUBTOTAL 8.B.2

[][][][]
9. Information in
relation to the
person subject to
the notification
obligation (please
mark the
applicable box
with an "X")
Person subject to
the notification
obligation is not
controlled by any
natural person or
legal entity and
does not control
any other
undertaking(s)
holding directly
or indirectly an
interest in the
(underlying)
issuer[xiii]
Full chain of x
controlled
undertakings
through which the
voting rights
and/or the
financial
instruments are
effectively held
starting with the
ultimate
controlling
natural person or
legal entity[xiv
](please add
additional rows as
necessary)
Name[xv] % of voting rights if it equals or is % of voting Total of
higher than the notifiable threshold rights both if it
through equals or
financial is higher
instruments than the
if it notifiable
equals or threshold
is higher
than the
notifiable
threshold
Timo Syrjälä 5.00% 5.00%
(Direct)
Acme Investments 12.27% 12.27%
SPF Sarl
(Indirect)

10. In case of
proxy voting,
please identify:
Name of the proxy
holder
The number and %
of voting rights
held
The date until
which the voting
rights will be
held

11. Additional
information[xvi]

Place of completion Luxembourg
Date of completion 31.01.2022